Adaptive Biotechnologies
Adaptive runs clonoSEQ, a blood test that tracks cancer relapse via immune DNA sequencing.
On the record
Checkpoint: Adaptive decides whether to spin off, sell, or keep its MRD and Immune Medicine businesses together
The call
Adaptive's cancer-monitoring test keeps growing and turned its first profit, while its data-licensing side lost its biggest partner and now leans on new Pfizer deals to prove it can stand alone.
Adaptive makes two things: clonoSEQ, a blood test that catches cancer relapse early and is used by hundreds of hospitals (this part is profitable and growing fast), and TCR technology that licenses genetic data to other drug makers (this part lost its main customer, Genentech, and is now tiny). The blood test is hard to replace because hospitals have wired it into their systems and insurance companies already pay for it, but Natera is chasing the same market in solid tumors and could move into blood cancers. The company plans to split in two by the end of 2026, and which half you join matters enormously for your job security and growth prospects. Watch the separation announcement closely and ask your hiring manager in writing which division you will belong to.
Why
01
AI pressure: General TCR-epitope prediction models (academic/lab AI tools). AI models that predict immune-epitope binding could replace Adaptive's sequencing data, but a 2025 Nature Methods benchmark shows they still generalize poorly. Could AI do the core job? Unlikely.
02
Bigger players: Natera (Signatera). Natera dominates solid-tumor MRD with ~$1B revenue and could push into blood cancers where Adaptive currently leads. Could a giant copy it? No, they are blocked.
03
What protects it. FDA clearance, 300M+ covered lives, 175+ EMR integrations, and payer contracts lock clonoSEQ into blood-cancer treatment workflows.
What would change this call
Adaptive's YE 2026 decision on separating MRD from Immune Medicine (spin, sale, or status quo). Reveals which business gets capital priority and how Immune Medicine's weakness is resolved.
Whether Immune Medicine signs a new recurring, non-milestone data-licensing deal after the Pfizer agreements. Would show it can rebuild stable revenue post-Genentech instead of relying on one-off milestones.
Natera or Guardant Health filing for FDA clearance of a hematologic (blood cancer) MRD test. Would show clonoSEQ's core moat in blood cancers is being directly challenged.
Whether Immune Medicine signs a new recurring, non-milestone data-licensing deal after the Pfizer agreements. Would show it can rebuild stable revenue post-Genentech instead of relying on one-off milestones.
Natera or Guardant Health filing for FDA clearance of a hematologic (blood cancer) MRD test. Would show clonoSEQ's core moat in blood cancers is being directly challenged.
Key numbers
- MRD revenue $67.1M in Q1, up 53% YoY
- FY2025 MRD revenue hit $212M, first profitable year
- Immune Medicine revenue fell to $3.5M after Genentech exit
Named risks
- Immune Medicine revenue collapsed 61% YoY after Genentech's 2025 exit with no confirmed recurring replacement deal.
- Separation into two entities by YE2026 could attach new hires to the weaker Immune Medicine side or unfavorable equity terms.
- Natera or Guardant could pursue FDA clearance in hematologic MRD, eroding Adaptive's core moat.
- $300M convertible note issuance (June 2026) adds dilution and debt-servicing considerations.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Natera | contesting | Signatera vendor-claimed ~$1B revenue leads solid-tumor MRD as of Feb 2026, but not hematologic MRD |
| Guardant Health | contesting | Won $292.5M jury verdict against Natera over MRD ad claims, June 2026 |
| Genentech | losing to | Terminated ~$2B TCR collaboration Aug 2025, effective Feb 2026, cutting Immune Medicine revenue |
| Exact Sciences and Illumina | gaining on | Cited by third-party analysis as intensifying oncology/MRD competition, Mar 2026 |
Questions people ask
- Is Adaptive Biotechnologies profitable in 2026?
- Not company-wide. The MRD segment hit adjusted EBITDA profitability for the first time in FY2025 ($15M), and Q1 2026 MRD revenue rose 53% YoY to $67.1M, but Immune Medicine remains loss-making after Genentech's August 2025 collaboration termination, per company filings dated 2026-05-05.
- Is Adaptive Biotechnologies splitting into two companies?
- Yes. On June 15, 2026, Adaptive announced plans to separate its profitable MRD diagnostics business (clonoSEQ) from its struggling Immune Medicine unit, with a preferred structure, spin-off, sale, or status quo, expected to be decided by year-end 2026.
- Who is Adaptive Biotechnologies' biggest competitor?
- Natera's Signatera dominates solid-tumor MRD testing (vendor-claimed roughly $1 billion revenue as of Feb 2026), while Guardant Health's Reveal also competes and won a $292.5M jury verdict against Natera in June 2026. Adaptive leads specifically in hematologic (blood cancer) MRD via FDA-cleared clonoSEQ.
- Could AI replace Adaptive Biotechnologies' TCR data business?
- Not yet. A Nature Methods benchmark published November 28, 2025 found general-purpose AI models generalize poorly to unseen TCR-epitope pairs (near-random accuracy), which is why Pfizer licensed Adaptive's proprietary TCR-antigen dataset in December 2025 rather than using public models.
- Did Adaptive Biotechnologies have layoffs?
- Yes, Adaptive cut 6.7% of its workforce in February 2024 amid a strategic review. Headcount has continued declining, from 829 in 2023 to about 665 by December 2025, according to workforce data published June 2026.
- What happened between Genentech and Adaptive Biotechnologies?
- Genentech terminated a roughly $2 billion potential TCR-based cell-therapy collaboration with Adaptive in August 2025, effective February 2026, following Roche's broader 2023 pullback from TCR therapies, sharply cutting Immune Medicine's recurring revenue.
Timeline
- 2026-06-17Prices upsized $300M 0% coupon convertible senior notes due 2031
- 2026-06-15Announces plan to separate MRD and Immune Medicine businesses
- 2026-05-05Q1 2026: MRD revenue $67.1M, up 53% YoY, guidance raised
- 2026-02-05Announces transition to Illumina NovaSeq X+ sequencing platform
- 2026-01-06Digital Biotechnologies subsidiary raises up to $15M Series A
- 2025-12-15Signs two Pfizer TCR licensing deals, up to $890M in milestones
- 2025-11-06Q3 2025 results: Immune Medicine revenue ex-termination fell 61% to $3.5M
- 2025-08Genentech terminates ~$2B TCR cell-therapy collaboration, effective Feb 2026
- 2024-02-226.7% workforce reduction tied to strategic review
- 2019-06-27IPOs on Nasdaq at $20/share, shares double on debut
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- MRD revenue surges 53%, guidance raised (2026-05-05)
- Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses (2026-06-15)
- EX-99.1 (Q1 2026 Financial Results) (2026-05-05)
- Adaptive Biotechnologies Q3 Revenues Double Due to MRD Business, Genentech Payment (2025-11-06)
- Genentech's Latest Layoffs Bring Total to Nearly 350 This Year (2025-10-29)
- Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses (2026-06-15)
- Adaptive Biotechnologies, Pfizer sign TCR deals, $890M milestones (2025-12-15)
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering (2026-06-17)
- Shares of Adaptive Biotechnologies double in hot IPO (2019-06-27)
- Adaptive Biotechnologies shapes $300m IPO (2019-06-28)
- Adaptive Biotechnologies (ADPT) to Post Earnings on Wednesday (2026-07-22)
- Adaptive Biotechnologies Layoffs (2024-02-22)